Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Non-Current Liabilities (2019 - 2025)

Immunocore Holdings' Total Non-Current Liabilities history spans 3 years, with the latest figure at $609.3 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 13.42% year-over-year to $609.3 million; the TTM value through Sep 2025 reached $609.3 million, down 13.42%, while the annual FY2024 figure was $648.8 million, 185.58% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $609.3 million at Immunocore Holdings, roughly flat from $609.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $703.8 million in Q3 2024 and bottomed at $227.2 million in Q4 2023.
  • The 3-year median for Total Non-Current Liabilities is $621.1 million (2024), against an average of $585.1 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 185.58% in 2024 before it dropped 13.42% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $227.2 million in 2023, then skyrocketed by 185.58% to $648.8 million in 2024, then fell by 6.08% to $609.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Total Non-Current Liabilities are $609.3 million (Q3 2025), $609.9 million (Q2 2025), and $587.1 million (Q1 2025).